Comparing clinical responses and the biomarkers of BDNF and cytokines between subthreshold bipolar disorder and bipolar II disorder

Patients with subthreshold hypomania (SBP; subthreshold bipolar disorder) were indistinguishable from those with bipolar disorder (BP)-II on clinical bipolar validators, but their analyses lacked biological and pharmacological treatment data. Because inflammation and neuroprogression underlies BP, w...

Full description

Bibliographic Details
Main Authors:	Wang, Tzu-Yun, Lee, Sheng-Yu, Chen, Shiou-Lan, Chang, Yun-Hsuan, Wang, Liang-Jen, Chen, Po See, Chen, Shih-Heng, Chu, Chun-Hsien, Huang, San-Yuan, Tzeng, Nian-Sheng, Li, Chia-Ling, Chung, Yi-Lun, Hsieh, Tsai-Hsin, Lee, I Hui, Chen, Kao Chin, Yang, Yen Kuang, Hong, Jau-Shyong, Lu, Ru-Band
Format:	Online
Language:	English
Published:	Nature Publishing Group 2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4895208/

id	pubmed-4895208
recordtype	oai_dc
spelling	pubmed-48952082016-06-10 Comparing clinical responses and the biomarkers of BDNF and cytokines between subthreshold bipolar disorder and bipolar II disorder Wang, Tzu-Yun Lee, Sheng-Yu Chen, Shiou-Lan Chang, Yun-Hsuan Wang, Liang-Jen Chen, Po See Chen, Shih-Heng Chu, Chun-Hsien Huang, San-Yuan Tzeng, Nian-Sheng Li, Chia-Ling Chung, Yi-Lun Hsieh, Tsai-Hsin Lee, I Hui Chen, Kao Chin Yang, Yen Kuang Hong, Jau-Shyong Lu, Ru-Band Article Patients with subthreshold hypomania (SBP; subthreshold bipolar disorder) were indistinguishable from those with bipolar disorder (BP)-II on clinical bipolar validators, but their analyses lacked biological and pharmacological treatment data. Because inflammation and neuroprogression underlies BP, we hypothesized that cytokines and brain-derived neurotrophic factor (BDNF) are biomarkers for BP. We enrolled 41 drug-naïve patients with SBP and 48 with BP-II undergoing 12 weeks of pharmacological treatment (valproic acid, fluoxetine, risperidone, lorazepam). The Hamilton Depression Rating Scale (HDRS) and Young Mania Rating Scale (YMRS) were used to evaluate clinical responses at baseline and at weeks 0, 1, 2, 4, 8, and 12. Inflammatory cytokines (tumour necrosis factor [TNF]-α, transforming growth factor [TGF]-β1, interleukin [IL]-6, IL-8 and IL-1β) and BDNF levels were also measured. Mixed models repeated measurement was used to examine the therapeutic effect and changes in BDNF and cytokine levels between the groups. HDRS and YMRS scores significantly (P < 0.001) declined in both groups, the SBP group had significantly lower levels of BDNF (P = 0.005) and TGF-β1 (P = 0.02). Patients with SBP and BP-II respond similarly to treatment, but SBP patients may have different neuroinflammation marker expression. Nature Publishing Group 2016-06-07 /pmc/articles/PMC4895208/ /pubmed/27270858 http://dx.doi.org/10.1038/srep27431 Text en Copyright © 2016, Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Wang, Tzu-Yun Lee, Sheng-Yu Chen, Shiou-Lan Chang, Yun-Hsuan Wang, Liang-Jen Chen, Po See Chen, Shih-Heng Chu, Chun-Hsien Huang, San-Yuan Tzeng, Nian-Sheng Li, Chia-Ling Chung, Yi-Lun Hsieh, Tsai-Hsin Lee, I Hui Chen, Kao Chin Yang, Yen Kuang Hong, Jau-Shyong Lu, Ru-Band
spellingShingle	Wang, Tzu-Yun Lee, Sheng-Yu Chen, Shiou-Lan Chang, Yun-Hsuan Wang, Liang-Jen Chen, Po See Chen, Shih-Heng Chu, Chun-Hsien Huang, San-Yuan Tzeng, Nian-Sheng Li, Chia-Ling Chung, Yi-Lun Hsieh, Tsai-Hsin Lee, I Hui Chen, Kao Chin Yang, Yen Kuang Hong, Jau-Shyong Lu, Ru-Band Comparing clinical responses and the biomarkers of BDNF and cytokines between subthreshold bipolar disorder and bipolar II disorder
author_facet	Wang, Tzu-Yun Lee, Sheng-Yu Chen, Shiou-Lan Chang, Yun-Hsuan Wang, Liang-Jen Chen, Po See Chen, Shih-Heng Chu, Chun-Hsien Huang, San-Yuan Tzeng, Nian-Sheng Li, Chia-Ling Chung, Yi-Lun Hsieh, Tsai-Hsin Lee, I Hui Chen, Kao Chin Yang, Yen Kuang Hong, Jau-Shyong Lu, Ru-Band
author_sort	Wang, Tzu-Yun
title	Comparing clinical responses and the biomarkers of BDNF and cytokines between subthreshold bipolar disorder and bipolar II disorder
title_short	Comparing clinical responses and the biomarkers of BDNF and cytokines between subthreshold bipolar disorder and bipolar II disorder
title_full	Comparing clinical responses and the biomarkers of BDNF and cytokines between subthreshold bipolar disorder and bipolar II disorder
title_fullStr	Comparing clinical responses and the biomarkers of BDNF and cytokines between subthreshold bipolar disorder and bipolar II disorder
title_full_unstemmed	Comparing clinical responses and the biomarkers of BDNF and cytokines between subthreshold bipolar disorder and bipolar II disorder
title_sort	comparing clinical responses and the biomarkers of bdnf and cytokines between subthreshold bipolar disorder and bipolar ii disorder
description	Patients with subthreshold hypomania (SBP; subthreshold bipolar disorder) were indistinguishable from those with bipolar disorder (BP)-II on clinical bipolar validators, but their analyses lacked biological and pharmacological treatment data. Because inflammation and neuroprogression underlies BP, we hypothesized that cytokines and brain-derived neurotrophic factor (BDNF) are biomarkers for BP. We enrolled 41 drug-naïve patients with SBP and 48 with BP-II undergoing 12 weeks of pharmacological treatment (valproic acid, fluoxetine, risperidone, lorazepam). The Hamilton Depression Rating Scale (HDRS) and Young Mania Rating Scale (YMRS) were used to evaluate clinical responses at baseline and at weeks 0, 1, 2, 4, 8, and 12. Inflammatory cytokines (tumour necrosis factor [TNF]-α, transforming growth factor [TGF]-β1, interleukin [IL]-6, IL-8 and IL-1β) and BDNF levels were also measured. Mixed models repeated measurement was used to examine the therapeutic effect and changes in BDNF and cytokine levels between the groups. HDRS and YMRS scores significantly (P < 0.001) declined in both groups, the SBP group had significantly lower levels of BDNF (P = 0.005) and TGF-β1 (P = 0.02). Patients with SBP and BP-II respond similarly to treatment, but SBP patients may have different neuroinflammation marker expression.
publisher	Nature Publishing Group
publishDate	2016
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4895208/
_version_	1613589689157025792

Comparing clinical responses and the biomarkers of BDNF and cytokines between subthreshold bipolar disorder and bipolar II disorder

Similar Items